• Home
  • Search Results

Search Results

432 studies match your search
Open

ONC-392 plus Lu 177 vipivotide in ARTA resistant mCRPC

Have you been diagnosed with Metastatic Castration-Resistant Prostate Cancer (mCRPC)? If so, you may be able to take part in a research study investigating if the study drug together with standard of care drug are safe and well tolerated, and whether two drugs are effective in treating prostate cancer, in comparison with standard of care alone.

Age & Gender
  • 18 years ~ 99 years
  • Male
Study Interest
  • Cancer (Prostate)
  • Men's Health

Autologous Anti-HER2 Chimeric Antigen Receptor Monocytes (CT-0525) in Participants with HER2 Over Expressing Solid Tumors

The purpose of this study is to learn about the effects of a research investigational product, CT-0525, and to see if CT-0525 is safe for participants with advanced cancer. This study is the first time that CT-0525 will be given to humans. CT-0525 is a special kind of product that is made of blood cells taken from your own body. Once collected, these blood cells will be altered and infused back into your body.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Phase 1 Trials (all cancers))

A study to test an oral medicine, belumosudil, in combination with corticosteroids in participants at least 12 years of age with newly diagnosed chronic graft versus host disease.

Primary Objective: Demonstrate the superiority of belumosudil in combination with prednisone vs placebo in combination with prednisone in Event-Free Survival (EFS) Secondary Objective:Demonstrate the superiority of belumosudil in combination with prednisone vs placebo incombination with prednisone in modified Lee Symptom Scale (mLSS) improvement,overall ,response rate (ORR) and in the rate of corticosteroid withdrawal

Age & Gender
  • 12 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Leukemia, Lymphoma)
  • Transplant
Open

A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy

Are you premenopausal and have been diagnosed with ER-positive, HER2-negative breast cancer and had surgery for your breast cancer? If so, you may be able to take part in a research study evaluating the addition of chemotherapy given after breast surgery with ovarian suppression and endocrine therapy versus ovarian suppression and endocrine therapy alone.

Age & Gender
  • 18 years ~ 99 years
  • Female, Gender Inclusive
Study Interest
  • Cancer (Breast)
Open

Cancer Family History in Black Families

The survey and its findings will help us understand attitudes around cancer family history and genetic testing among Black people. This information will be used to develop an educational curriculum to strive towards health equity for Black people diagnosed with or at higher risk of cancer and get Black people the best cancer care.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Bladder, Brain and Other Nervous System, Breast, and 18 more)
  • Healthy Volunteer or General Population
  • Minority Health
Visit Location
100% Remote (online, phone, text)
Open

SPECT-CT Guided Elective Contralateral Neck Treatment for Pts With Lateralized Oropharyngeal Cancer

Have you been diagnosed with Lateralized Oropharyngeal Cancer . If so, you may be able to take part in a research study looking at the safety by using a special imaging study called lymph node mapping (lymphatic mapping) Single Photon Emission Computed Tomography (SPECT-CT) compared to the usual treatment when radiotherapy is given .

Age & Gender
  • 18 years ~ 99 years
  • Male, Female
Study Interest
  • Cancer (Head and Neck)
Open

Reduced Dose of Cyclophosphamide to Prevent Graft versus Host Disease after Stem Cell Transplant

Do you have AML, ALL, or MDS, and are preparing for a stem cell transplant from an unrelated donor? If so, you might be able to take part in a study to will see if a reduced dose of a drug called cyclophosphamide will still reduce your chances of developing Graft versus Host disease, but also lower your chances of side effects from the drug.

Age & Gender
  • 18 years ~ 65 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Leukemia, Lymphoma)
  • Transplant

A Comparator Study of a Tasso device to traditional venous blood sampling methods for CBC in patients with leukemia, lymphoma, or other blood cell disorders

This study will evaluate the feasibility of using capillary blood samples collected with the Tasso device for analysis of CBC in diseased patients with leukemia, lymphoma, and/or other blood cell disorders.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Blood Conditions
  • Cancer (Leukemia, Lymphoma)
Open

Phase I Study of CAR-T Cells Targeting the B7-H3 Antigen in Patients with Refractory Pancreatic Ductal Adenocarcinoma (PDAC)

Do you have pancreatic ductal adenocarcinoma that has come back after receiving standard therapy? If so, you may be able to participate in this gene therapy research study to learn more about using you own modified immune cells as possible treatment.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female
Study Interest
  • Cancer (Pancreatic)

Daratumumab infusion reaction study for patients with multiple myeloma

The purpose of this research study is to learn more about the risk of severe and fatal infusion-related reactions (IRR) in patients with multiple myeloma who are treated with their first 3 administrations of daratumumab. Examples of severe IRR include lung tightness, low oxygen levels, difficulty breathing, high blood pressure, racing heart, headache, and too much fluid in the lungs. No fatal IRRs have been observed in clinical trials of daratumumab. We are also doing this study to help us to identify potential risk factors for IRR.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Multiple Myeloma)
Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research